Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax in Relapsed/Refractory CLL (VENICE II)
NCT02980731Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2016
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of venetoclax in chronic lymphocytic leukemia (CLL), sponsored by AbbVie Inc. Primary endpoint: Global Health Status/Quality of Life Subscale of EORTC QLQ-C30 at 48 weeks. Started Dec 2016; status: completed.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02980731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02980731.